Four 2025 trials spanning novel antibiotic dosing, rapid diagnostics, immunomodulator comparison in COVID-19, and corticosteroids in severe CAP, summarized in full CCR 11-part format.
DOTS — Dalbavancin for Treatment of S. aureus BacteremiaMULTI-CAP — Multiplex PCR + Procalcitonin to Reduce Antibiotic Exposure in CAPREMAP-CAP Immune Modulation — Tocilizumab, Sarilumab, Anakinra in Critical COVID-19REMAP-CAP Corticosteroid Domain — Hydrocortisone in Severe CAP🦠